Skin replacement therapy - Stratatech

Drug Profile

Skin replacement therapy - Stratatech

Alternative Names: StrataGraft

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator University of Wisconsin System; Wisconsin Alumni Research Foundation
  • Developer Stratatech
  • Class Cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Burns
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Burns
  • Phase I/II Wounds

Most Recent Events

  • 22 Dec 2016 Stratatech plans a phase II trial for Burns and Wounds in USA (NCT03005054)
  • 31 Aug 2016 Stratatech has been acquired by Mallinckrodt plc
  • 31 Aug 2016 Phase-III clinical trials in Burns in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top